{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:02:34Z","timestamp":1789707754367,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>SCN4A encodes the skeletal-muscle voltage-gated sodium channel NaV1.4. Pathogenic variation in this gene produces fundamentally different disease mechanisms, including dominant alpha-pore gain of function, dominant S4 gating-pore currents, and reduced channel availability, with severe biallelic loss of function causing congenital myopathy and fetal hypokinesia. This heterogeneity makes variant interpretation difficult because formal variant classification, the direction of channel dysfunction, and patient-level disease attribution are closely related but distinguishable conclusions. In this review, we synthesize the clinical, genetic, electrophysiological, structural, and functional evidence relevant to SCN4A variant interpretation, with particular attention to missense variants of uncertain significance. We examine how inheritance, channel topology, phenotype, population data, segregation, RNA evidence, regional and residue-level context, and mechanism-matched functional assays can be integrated within the ACMG\/AMP framework. Published pathogenic-enriched regions, gnomAD regional missense constraint, and same-residue observations may contribute to variant interpretation when the requirements of an applicable ACMG\/AMP criterion are met; when they have not been specifically validated or calibrated for SCN4A, they are best used as contextual information to prioritize additional evidence generation. Based on this literature, we organize these evidence domains into a practical phenotype-first, mechanism-informed workflow for SCN4A variant interpretation. This workflow is not intended as an alternative to or extension of ACMG\/AMP but as an SCN4A-specific application of established variant-interpretation principles in a gene associated with multiple inheritance patterns and directionally distinct disease mechanisms. After technical confirmation of a candidate variant, as well as phenotype and inheritance context guide selection of the relevant disease model, appropriately validated functional evidence may contribute directly to ACMG\/AMP classification, while functional mechanism and patient-level disease attribution are documented as related but distinguishable interpretative outputs. The same approach applies when a variant is identified through genotype-first sequencing: interpretation should return to deliberate phenotyping, inheritance assessment, electrophysiological characterization, and consideration of the differential diagnosis before disease causality is inferred.<\/jats:p>","DOI":"10.3390\/genes17091116","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:01:00Z","timestamp":1789405260000},"page":"1116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SCN4A Channelopathies: From Disease Mechanisms to Variant Interpretation"],"prefix":"10.3390","volume":"17","author":[{"given":"Paola","family":"D\u2019Ambrosio","sequence":"first","affiliation":[{"name":"Medical and Molecular Genetics, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cipriano","sequence":"additional","affiliation":[{"name":"Medical and Molecular Genetics, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-3953","authenticated-orcid":false,"given":"Roberta","family":"Petillo","sequence":"additional","affiliation":[{"name":"Medical and Molecular Genetics, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-4165","authenticated-orcid":false,"given":"Dario","family":"Ricciardi","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-3393","authenticated-orcid":false,"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-9550","authenticated-orcid":false,"given":"Manuela","family":"Priolo","sequence":"additional","affiliation":[{"name":"Medical and Molecular Genetics, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/164_2017_52","article-title":"Sodium channelopathies of skeletal muscle","volume":"246","author":"Cannon","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1152\/physrev.00025.2020","article-title":"Sodium channelopathies of skeletal muscle and brain","volume":"101","author":"Mantegazza","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0092-8674(91)90374-8","article-title":"Identification of a mutation in the gene causing hyperkalemic periodic paralysis","volume":"67","author":"George","year":"1991","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Maggi, L., Bonanno, S., Altamura, C., and Desaphy, J.F. (2021). Ion channel gene mutations causing skeletal muscle disorders: Pathomechanisms and opportunities for therapy. Cells, 10.","DOI":"10.3390\/cells10061521"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1212\/WNL.0b013e3181ed9e96","article-title":"Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: A new treatable disorder","volume":"75","author":"Mignot","year":"2010","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1073\/pnas.1230273100","article-title":"Myasthenic syndrome caused by mutation of the SCN4A sodium channel","volume":"100","author":"Tsujino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/brain\/awv352","article-title":"Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or \u201cclassical\u201d congenital myopathy","volume":"139","author":"Zaharieva","year":"2016","journal-title":"Brain"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Maggi, L., Brugnoni, R., Canioni, E., Tonin, P., Saletti, V., Sola, P., Piccinelli, S.C., Colleoni, L., Ferrigno, P., and Pini, A. (2020). Clinical and molecular spectrum of myotonia and periodic paralyses associated with mutations in SCN4A in a large cohort of Italian patients. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00646"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1212\/WNL.0b013e318219fb57","article-title":"Leaky sodium channels from voltage sensor mutations in periodic paralysis, but not paramyotonia","volume":"76","author":"Francis","year":"2011","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/gim.2017.210","article-title":"Modeling the ACMG\/AMP variant-classification guidelines as a Bayesian classification framework","volume":"20","author":"Tavtigian","year":"2018","journal-title":"Genet. Med."},{"key":"ref_12","unstructured":"Clinical Genome Resource (2026, August 01). SCN4A\u2013SCN4A-Related Myopathy, Autosomal Recessive: Gene\u2013Disease Validity Curation. Classification Date: 13 May 2021. Available online: https:\/\/search.clinicalgenome.org\/CCID:006074."},{"key":"ref_13","unstructured":"Clinical Genome Resource (2026, August 01). Criteria Specification Registry. Available online: https:\/\/cspec.genome.network\/cspec\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/humu.23626","article-title":"Recommendations for interpreting the loss-of-function PVS1 ACMG\/AMP variant criterion","volume":"39","author":"Pesaran","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41598-018-20468-0","article-title":"Substitutions of the S4DIV R2 residue (R1451) in NaV1.4 lead to complex forms of paramyotonia congenita and periodic paralyses","volume":"8","author":"Poulin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajhg.2023.11.009","article-title":"ClinGen guidance for use of the PP1\/BS4 co-segregation and PP4 phenotype-specificity criteria for sequence variant pathogenicity classification","volume":"111","author":"Biesecker","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","article-title":"Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria","volume":"109","author":"Pejaver","year":"2022","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2017.26","article-title":"Using high-resolution variant frequencies to empower clinical genome interpretation","volume":"19","author":"Whiffin","year":"2017","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajhg.2023.06.002","article-title":"Using the ACMG\/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup","volume":"110","author":"Walker","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"D1313","DOI":"10.1093\/nar\/gkae1090","article-title":"ClinVar: Updates to support classifications of both germline and somatic variants","volume":"53","author":"Landrum","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41431-021-00959-x","article-title":"The LOVD3 platform: Efficient genome-wide sharing of genetic variants","volume":"29","author":"Fokkema","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1101\/gr.252601.119","article-title":"Identification of pathogenic variant enriched regions across genes and gene families","volume":"30","author":"May","year":"2020","journal-title":"Genome Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Samocha, K.E., Kosmicki, J.A., Karczewski, K.J., O\u2019Donnell-Luria, A.H., Pierce-Hoffman, E., MacArthur, D.G., Neale, B.M., and Daly, M.J. (2017). Regional missense constraint improves variant deleteriousness prediction. bioRxiv, 148353.","DOI":"10.1101\/148353"},{"key":"ref_25","unstructured":"(2026, August 01). Genome Aggregation Database (gnomAD) Regional Missense Constraint Metric in, g.n.o.m.A.D. Available online: https:\/\/gnomad.broadinstitute.org\/news\/2023-11-gnomad-v2-rmc\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/pan.12217","article-title":"Pathophysiologic and anesthetic considerations for patients with myotonia congenita or periodic paralyses","volume":"23","author":"Bandschapp","year":"2013","journal-title":"Paediatr. Anaesth."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1213\/ane.0b013e3181a7c8e5","article-title":"The myotonias and susceptibility to malignant hyperthermia","volume":"109","author":"Parness","year":"2009","journal-title":"Anesth. Analg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41436-019-0686-8","article-title":"Technical standards for the interpretation and reporting of constitutional copy-number variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Clinical Genome Resource","volume":"22","author":"Riggs","year":"2020","journal-title":"Genet. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-019-0690-2","article-title":"Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2020","journal-title":"Genome Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"eaal5209","DOI":"10.1126\/scitranslmed.aal5209","article-title":"Improving genetic diagnosis in Mendelian disease with transcriptome sequencing","volume":"9","author":"Cummings","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajhg.2019.01.012","article-title":"Expanding the boundaries of RNA sequencing as a diagnostic tool for rare Mendelian disease","volume":"104","author":"Gonorazky","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fujiwara, K., Yamamoto, R., Kubota, T., Tazumi, A., Sabuta, T., Takahashi, M.P., and Sakurai, H. (2022). Mature myotubes generated from human-induced pluripotent stem cells without forced gene expression. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.886879"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: A randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: A double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e31823a0cb6","article-title":"Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype","volume":"77","author":"Matthews","year":"2011","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Aguti","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_38","unstructured":"Human Protein Atlas (2026, August 01). SCN4A Protein Expression Summary. Available online: https:\/\/www.proteinatlas.org\/ENSG00000007314-SCN4A."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:15:24Z","timestamp":1789704924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["genes17091116"],"URL":"https:\/\/doi.org\/10.3390\/genes17091116","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}